PTC Therapeutics, Inc. EBIT

EBIT of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.


Highlights and Quick Summary

  • EBIT for the quarter ending June 29, 2021 was $-98.5 Million (a 0.35% increase compared to previous quarter)
  • Year-over-year quarterly EBIT increased by 78.65%
  • Annual EBIT for 2020 was $-605 Million (a 56.89% increase from previous year)
  • Annual EBIT for 2019 was $-386 Million (a 66.66% increase from previous year)
  • Annual EBIT for 2018 was $-231 Million (a 79.94% increase from previous year)
  • Twelve month EBIT ending June 29, 2021 was $-348 Million (a -20.32% decrease compared to previous quarter)
  • Twelve month trailing EBIT decreased by -14.71% year-over-year
Trailing EBIT for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-348 Million $-437 Million $-432 Million $-408 Million
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of PTC Therapeutics, Inc.

Most recent EBITof PTCT including historical data for past 10 years.

Interactive Chart of EBIT of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-98.49 $-98.15
2020 $-96.37 $-55.13 $-187.27 $-92.99 $-604.95
2019 $-72.79 $-60.48 $-38.76 $-69.14 $-385.6
2018 $-45.14 $-48.23 $-5.57 $-16.74 $-231.37
2017 $5.45 $-30.89 $-12.5 $-26.36 $-128.58
2016 $-24.99 $-32.06 $-36.56 $-38.44 $-259.12
2015 $-48.2 $-42.23 $-38.63 $-38.07 $-167.13
2014 $-32.23 $-27.6 $-25.37 $-14.21 $-99.41
2013 $-18.09 $-4.28 $-14.45 $-8.58 $-45.4
2012 $-6.04 $-7.06 $-7.5 $-6.22 $-26.81
2011 $30.58

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.